<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03895996</url>
  </required_header>
  <id_info>
    <org_study_id>AVT001-T1D-01</org_study_id>
    <nct_id>NCT03895996</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes</brief_title>
  <official_title>A Phase 1 / 2 Double-Blind, Randomized, Placebo Controlled Study of Safety, Tolerability and Potential Efficacy of AVOTRES Cell-Based Therapy (AVT001) in Patients With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avotres Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avotres Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized , placebo-controlled study to evaluate the safety and
      tolerability of AVT001, and to assess AVT001 as a potential treatment for type 1 diabetes
      (T1D). The trial will involve approximately 24 new-onset T1D subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of treatment-emergent adverse events</measure>
    <time_frame>5 months post first dose</time_frame>
    <description>Safety/tolerability outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline of clinical parameters on CBC/differential, chemistry panel</measure>
    <time_frame>5 months post first dose</time_frame>
    <description>Safety/tolerability outcomes - the clinical parameters tested include creatinine, AST, ALT, and total bilirubin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence and severity of local i.v.-site reactions,</measure>
    <time_frame>5 months post first dose</time_frame>
    <description>Safety/tolerability outcomes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the HLA-E-restricted CD8+ T cell regulatory activity (&quot;potency assay&quot;)</measure>
    <time_frame>5 months post first dose</time_frame>
    <description>Efficacy outcomes - &quot;potency assay&quot; measures the activity of CD8+ T regulatory cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in the area under the curve (AUC) of the stimulated C-peptide levels over a 4-hour mixed meal tolerance test (MMTT)</measure>
    <time_frame>5 months post first dose</time_frame>
    <description>Efficacy outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in HbA1c</measure>
    <time_frame>5 months post first dose</time_frame>
    <description>Efficacy outcomes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>AVT001 (Treatment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion of AVT001 (treatment) in monthly doses x 3, 7x10^6-10x10^6 cells/dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Infusion of AVT001-matched placebo in monthly doses x 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AVT001</intervention_name>
    <description>autologous dendritic cell therapy</description>
    <arm_group_label>AVT001 (Treatment)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matched placebo</description>
    <arm_group_label>Matched placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Diagnosis of type 1 diabetes, within 12 months of first dosing, confirmed by positive
             lab result for one or more of the following types of autoantibodies:

               1. Glutamic acid decarboxylase (GAD65)

               2. Insulinoma associated protein 2 (IA-2, also known as ICA-512)

               3. Zinc transporter 8 (ZnT8).

          2. Age 18 or older and able to provide informed consent.

          3. If a participant is female with reproductive potential, willing to avoid pregnancy
             through the duration of the trial.

          4. Signed and dated written informed consent.

        Key Exclusion Criteria:

          1. Poorly controlled diabetes despite insulin therapy, who in the opinion of the
             investigator would not be a good candidate for participation in a clinical trial

          2. Screening hemoglobin &lt;10.0 g/dL; leukocytes &lt;3,000/uL; neutrophils &lt;1,500/uL;
             lymphocytes &lt;800/uL; platelets &lt;100,000/uL

          3. Screening Urine Albumin Excretion &gt; 300mg/gmCr

          4. Screening eGFR &lt; 60 mL/min/1.73m2

          5. Screening ALT or AST &gt; 1.5x upper limit of normal (ULN)

          6. Screening bilirubin &gt; 2.0 mg / dL

          7. Current use of immunosuppressive or immunomodulatory therapies, including
             pharmacologic doses of systemic steroids. However, topical steroidal creams and
             inhaled steroids without large systemic absorption are allowed.

          8. Coincident medical condition likely to require immunosuppressive or immunomodulatory
             therapies.

          9. Coincident medical condition likely to limit short term (5 year) life expectancy
             (malignancy, symptomatic coronary artery disease, recent stroke)

         10. Prior radiation therapy, immunotherapy (within 1 year of screening), or chemotherapy

         11. Serologic evidence of current HIV-1 or HIV-2 infection

         12. Serologic evidence of hepatitis C infection

         13. Serologic evidence of acute or chronic active hepatitis B as measured by Core Ab
             positive and / or Surface Antibody antigen positive

         14. Subjects with other autoimmune conditions (except compensated or treated autoimmune
             thyroid, celiac, alopecia, or vitiligo diseases)

         15. Women who are pregnant (pregnancy testing during screening), breastfeeding, or
             planning pregnancy during the study period

         16. Inadequate venous access to support leukapheresis

         17. Any condition that in the opinion of the investigator(s) would preclude the subject
             from participating in a clinical trial.

         18. Abnormal screening ECG that in the opinion of the investigator or sponsor would pose a
             safety risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Gaglia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Joslin Diabetes Center, Harvard Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jason Gaglia, MD</last_name>
    <phone>888-813-8669</phone>
    <email>T1DTrials@joslin.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Joslin Diabetes Center, Harvard Medical School</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Gaglia, MD, MMSc</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 15, 2019</study_first_submitted>
  <study_first_submitted_qc>March 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2019</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

